Chevy Chase Trust Holdings LLC Sells 77,760 Shares of Johnson & Johnson (NYSE:JNJ)

Chevy Chase Trust Holdings LLC reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,399,101 shares of the company's stock after selling 77,760 shares during the period. Johnson & Johnson makes up 0.6% of Chevy Chase Trust Holdings LLC's investment portfolio, making the stock its 25th largest holding. Chevy Chase Trust Holdings LLC owned about 0.06% of Johnson & Johnson worth $202,338,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of JNJ. Asset Planning Inc bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $795,000. Vicus Capital grew its holdings in Johnson & Johnson by 1.9% during the fourth quarter. Vicus Capital now owns 5,464 shares of the company's stock worth $790,000 after buying an additional 104 shares in the last quarter. Banque Pictet & Cie SA raised its position in Johnson & Johnson by 10.7% in the 4th quarter. Banque Pictet & Cie SA now owns 178,474 shares of the company's stock valued at $25,811,000 after buying an additional 17,282 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Johnson & Johnson by 3.9% during the 4th quarter. V Square Quantitative Management LLC now owns 47,319 shares of the company's stock valued at $6,843,000 after acquiring an additional 1,778 shares in the last quarter. Finally, CFC Planning Co LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $1,920,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Remove Ads

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Raymond James cut their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Finally, Wells Fargo & Company cut their price objective on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.67.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $2.67 during trading hours on Friday, hitting $162.35. The company's stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business has a 50 day simple moving average of $148.93 and a two-hundred day simple moving average of $155.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the company earned $2.29 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.